Article
Polymorphisms of peroxisome proliferator-activated receptor γ (PPARγ) and cluster of differentiation 36 (CD36) associated with valproate-induced obesity in epileptic patients.
Psychopharmacology - 1 Sept 2018
Bai Xupeng, Xu Chuncao, Wen Dingsheng, Chen Yibei, Li Hongliang, Wang Xueding, Zhou Liemin, Huang Min, Jin Jing
Abstract excerpt
RATIONALE: Valproate (VPA) is a choice for the treatment of primary generalized epilepsies and partial epilepsies. Unfortunately, weight gain or obesity is one of the most frequent adverse effects of VPA treatment. Genetic factors were shown to be involved in the effect. OBJECTIVE: The aim of this study was to investigate the association of selected single nucleotide polymorphisms (SNPs) of cluster of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.